MedPath

Propofol during Minimal Invasive Surfactant Evaluation Study

Completed
Conditions
Respiratory Distress Syndrome
10038686
10028920
Registration Number
NL-OMON40970
Lead Sponsor
eonatologie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
78
Inclusion Criteria

Preterm infants (26-37 weeks of gestation) needing surfactant therapy for RDS according to local criteria (FiO2 > 30% and PEEP > 8).

Exclusion Criteria

Imminent need for intubation because of respiratory distress, apnea or persistent acidosis.
Infants who suffer from pneumothorax or pulmonary hemorrhage.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The main study parameter is the comfort-neo score, the primary endpoint is the<br /><br>percentage of infants with a comfort-neo score below 14 during the procedure.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary study parameters are;<br /><br>- Occurrence of positive pressure ventilation during and right after the<br /><br>procedure;<br /><br>- Occurrence of intubation needed during the procedure and within 24 hours;<br /><br>- Number of attempts of endotracheal insertion of angiocatheter;<br /><br>- Duration of the total procedure (from start inserting laryngoscope, until<br /><br>exit angiocatheter);<br /><br>- Complications occurring during the procedure: desaturation < 85%, hypotension<br /><br>(mean below gestational age), bradycardia < 80 bpm, nasal hemorrhage;<br /><br>- Other complications: pneumothorax, pulmonary haemorrhage, resuscitation;<br /><br>- Heart rate and blood pressure before, during and 5 minutes after the<br /><br>procedure.</p><br>
© Copyright 2025. All Rights Reserved by MedPath